[(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid – (847499-27-8)

Delanzomib, 847499-27-8, CEP-18770, CEP 18770, CT-47098, NPH007098, Delanzomib [USAN:INN], NPH 007098, Delanzomib [USAN], Delanzomib (CEP-18770), delanzomibum, UNII-6IF28942WO, ((R)-1-((2S, 3R)-3-Hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutyl)boronic acid, 6IF28942WO, Delanzomib (USAN), DELANZOMIB [INN], CIP 18770, CIP-18770, NPH-007098, DELANZOMIB [WHO-DD], CT 47098, CHEMBL270515, [(1R)-1-[(2S, 3R)-3-hydroxy-2-[(6-phenylpyridin-2-yl)formamido]butanamido]-3-methylbutyl]boronic acid, CHEBI:141530, Boronic acid, ((1R)-1-(((2S, 3R)-3-hydroxy-1-oxo-2-(((6-phenyl-2-pyridinyl)carbonyl)amino)butyl)amino)-3-methylbutyl)-, [(1R)-1-[[(2S, 3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid, [(1R)-1-[[(2S, 3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid, [(1R)-3-methyl-1-({N-[(6-phenylpyridin-2-yl)carbonyl]-L-threonyl}amino)butyl]boronic acid, ((1R)-1-(((2s, 3r)-3-hydroxy-2-(((6-phenylpyridin-2-yl)carbonyl)amino)-1-oxobutyl)amino)-3-methylbutyl)boronic acid, ((1R)-1-((2S, 3R)-3-HYDROXY-2-(6-PHENYLPYRIDINE-2-CARBOXAMIDO)BUTANAMIDO)-3-METHYLBUTYL)BORONIC ACID, [(1R)-1-[[(2S, 3R)-3-hydroxy-1-oxo-2-[[oxo-(6-phenyl-2-pyridyl)methyl]amino]butyl]amino]-3-methylbutyl]boronic acid, [(1R)-1-[[(2S, 3R)-3-hydroxy-2-[(6-phenylpyridin-2-yl)carbonylamino]butanoyl]amino]-3-methyl-butyl]boronic acid, [(1R)-1-[[(2S, 3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid., B-((1R)-1-((N-((6-PHENYLPYRIDIN-2-YL)CARBONYL)-L-THREONYL)AMINO)-3-METHYLBUTYL)BORONIC ACID, BORONIC ACID, B-((1R)-1-(((2S, 3R)-3-HYDROXY-1-OXO-2-(((6-PHENYL-2-PYRIDINYL)CARBONYL)AMINO)BUTYL)AMINO)-3-METHYLBUTYL)-, CEP-18770 (Delanzomib), ((1R)-3-methyl-1-((N-((6-phenylpyridin-2-yl)carbonyl)-L-threonyl)amino)butyl)boronic acid, ((1R)-1-(((2S, 3R)-3-hydroxy-1-oxo-2-((oxo-(6-phenyl-2-pyridyl)methyl)amino)butyl)amino)-3-methylbutyl)boronic acid, ((1R)-1-(((2S, 3R)-3-hydroxy-2-((6-phenylpyridin-2-yl)carbonylamino)butanoyl)amino)-3-methyl-butyl)boronic acid, ((1R)-1-((2S, 3R)-3-hydroxy-2-((6-phenylpyridin-2-yl)formamido)butanamido)-3-methylbutyl)boronic acid, Delanzomib, free base, CEP-18770 Delanzomib, Delanzomib(CEP-18770)?, SCHEMBL555047, DTXSID901025656, Proteasome Inhibitor CEP 18770, EX-A2040, BDBM50329819, NSC764334, AKOS022185107, CS-1624, DB11956, NSC-764334, NCGC00346469-01, NCGC00346469-02, NCGC00346469-05, NCGC00346469-08, AC-24847, HY-10454, MS-27143, NS00073518, D10110, F84973, BRD-K59325863-001-01-0, BRD-K59325863-001-02-8, BRD-K59325863-001-03-6, Q27264956, (R)-1-((2S, 3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutylboronic acid, [(1R)-1-[[(2S, 3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid